Previous close | 523.57 |
Open | 531.00 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 520.40 - 531.00 |
52-week range | 308.40 - 600.90 |
Volume | |
Avg. volume | 103,234 |
Market cap | 386.419M |
Beta (5Y monthly) | 0.63 |
PE ratio (TTM) | 0.13 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
BOSTON & BASEL, Switzerland, June 26, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Lonza (SIX: LONN) today announced a strategic collaboration to support the manufacture of Vertex’s portfolio of investigational stem cell-derived, fully differentiated insulin-producing islet cell therapies for people with T1D, currently focusing on the VX-880 and VX-264 programs that are currently in clinical trials.